Home » Market News » DirectorsTalk Highlights » Panmure Gordon Analyst comments on Immupharma PLC this morning
Immupharma Plc

Panmure Gordon Analyst comments on Immupharma PLC this morning

Panmure Gordon Analyst Dr Mike Mitchell this morning said about Immupharma PLC “This morning ImmuPharma has announced the commencement of dosing in the first European patients in the company’s pivotal Phase III clinical study for Lupuzor™. This means that both US and European sites are now dosing patients in the Phase III trial (recruitment is expected in up to 45 investigator sites) and with Lupus continuing to represent a major unmet medical need we consider the ongoing demand for an effective treatment – highlighted by still torpid sales of GSK’s Benlysta – represents a major opportunity for ImmuPharma and Lupuzor™. “

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.